NASDAQ:TYRA Tyra Biosciences (TYRA) Stock Forecast, Price & News $13.46 -0.38 (-2.75%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$13.19▼$14.0050-Day Range$13.15▼$16.0852-Week Range$5.50▼$19.74Volume57,472 shsAverage Volume39,139 shsMarket Capitalization$578.91 millionP/E RatioN/ADividend YieldN/APrice Target$24.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tyra Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside78.3% Upside$24.00 Price TargetShort InterestBearish9.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.38Based on 3 Articles This WeekInsider TradingSelling Shares$772,507 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.32) to ($1.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector718th out of 964 stocksPharmaceutical Preparations Industry321st out of 438 stocks 3.5 Analyst's Opinion Consensus RatingTyra Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, Tyra Biosciences has a forecasted upside of 78.3% from its current price of $13.46.Amount of Analyst CoverageTyra Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.73% of the float of Tyra Biosciences has been sold short.Short Interest Ratio / Days to CoverTyra Biosciences has a short interest ratio ("days to cover") of 22.9, which indicates bearish sentiment.Change versus previous monthShort interest in Tyra Biosciences has recently increased by 1.12%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTyra Biosciences does not currently pay a dividend.Dividend GrowthTyra Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TYRA. Previous Next 3.0 News and Social Media Coverage News SentimentTyra Biosciences has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Tyra Biosciences this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $772,507.00 in company stock.Percentage Held by Insiders18.40% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.32) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tyra Biosciences is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tyra Biosciences is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTyra Biosciences has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tyra Biosciences (NASDAQ:TYRA) StockTyra Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 which is in Phase 1/2 clinical trial for the treatment of patients with mUC and other solid tumors. The company is also developing TYRA-300 for long-term complications associated with skeletal conditions including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes. Its product pipeline also includes TYRA-200, an FGFR1/2/3 inhibitor with potency FGFR2 fusions and molecular brake mutations for bile duct and solid tumors; FGF19+/FGFR4, a FGFR4-specific inhibitor that is active in the presence of the V550 gatekeeper and the C552 Cys mutations for liver and solid tumors; and RET, a specific inhibitor that is active in the presence of the V804 gatekeeper and the G810 solvent front mutations for the treatment of lung and thyroid cancer. The company was incorporated in 2018 and is headquartered in Carlsbad, California.Read More TYRA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TYRA Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Shares Up 4.8%September 21, 2023 | finance.yahoo.comTyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual MeetingsSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 16, 2023 | barrons.comTyra Biosciences Inc.September 12, 2023 | finance.yahoo.comTyra Biosciences to Participate at 2023 Cantor Global Healthcare ConferenceAugust 29, 2023 | msn.comTyra Biosciences: FDA ODD Designation Progresses TYRA-300August 11, 2023 | markets.businessinsider.comAnalyst Ratings for Tyra BiosciencesAugust 11, 2023 | finanznachrichten.deTyra Biosciences, Inc.: Tyra Biosciences Reports Second Quarter 2023 Financial Results and HighlightsSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 11, 2023 | finance.yahoo.comTyra Biosciences Reports Second Quarter 2023 Financial Results and HighlightsAugust 3, 2023 | marketwatch.comTyra Biosciences Gets FDA Orphan Designation for TYRA-300 in Achondroplasia >TYRAAugust 3, 2023 | msn.comTyra Biosciences gets FDA orphan drug designation for dwarfism therapyAugust 1, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Tyra Bioscience (TYRA)June 30, 2023 | benzinga.comWedbush Initiates Coverage On Tyra Biosciences with Outperform Rating, Announces Price Target of $27June 16, 2023 | finance.yahoo.comHere's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price StrengthJune 7, 2023 | finance.yahoo.comWall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a BetJune 1, 2023 | seekingalpha.comTyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective MoleculesMay 23, 2023 | finance.yahoo.comWhat Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'May 22, 2023 | finance.yahoo.comWall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to TradeMay 8, 2023 | markets.businessinsider.comWhere Tyra Biosciences Stands With AnalystsMay 5, 2023 | marketwatch.comTyra Biosciences Reports First Quarter 2023 Financial Results and HighlightsMay 5, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Tyra Bioscience (TYRA)March 29, 2023 | finance.yahoo.comTyra Biosciences to Participate in Upcoming Investor ConferencesMarch 27, 2023 | finance.yahoo.comHere's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)March 23, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Tyra BiosciencesMarch 23, 2023 | markets.businessinsider.comTyra Bioscience (TYRA) Gets a Buy from H.C. WainwrightMarch 22, 2023 | finance.yahoo.comTyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and HighlightsSee More Headlines Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TYRA Company Calendar Last Earnings8/10/2023Today9/27/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TYRA CUSIPN/A CIK1863127 Webwww.tyra.bio Phone619-728-4760FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Stock Price Forecast$24.00 High Stock Price Forecast$27.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+78.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-19.96% Return on Assets-19.31% Debt Debt-to-Equity RatioN/A Current Ratio44.54 Quick Ratio44.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.11 per share Price / Book2.20Miscellaneous Outstanding Shares43,011,000Free Float35,097,000Market Cap$578.93 million OptionableNot Optionable Beta0.90 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Todd Harris Ph.D. (Age 44)Co-Founder, Pres, CEO, Sec., Treasurer & Director Comp: $903.33kMr. Daniel Bensen (Age 48)Co-Founder & COO Comp: $630.8kMr. Ali D. Fawaz J.D.Gen. Counsel & Sec.Mr. Alan Fuhrman (Age 66)Chief Financial Officer Dr. Robert L. Hudkins Ph.D. (Age 68)Chief Technology Officer Dr. Ronald V. Swanson Ph.D. (Age 60)Chief Scientific Officer Ms. Sarah HonigVP of Corp. Devel. & StrategyDr. Hiroomi Tada M.D. (Age 59)Ph.D., Chief Medical Officer Dr. Piyush R. Patel Ph.D. (Age 58)Chief Devel. Officer Amy ConradInvestor ContactMore ExecutivesKey CompetitorsPhathom PharmaceuticalsNASDAQ:PHATRAPT TherapeuticsNASDAQ:RAPTAlpine Immune SciencesNASDAQ:ALPNEnliven TherapeuticsNASDAQ:ELVNCentessa PharmaceuticalsNASDAQ:CNTAView All CompetitorsInsiders & InstitutionsBarclays PLCSold 3,997 shares on 9/21/2023Ownership: 0.006%Perceptive Advisors LLCSold 134,403 shares on 8/24/2023Ownership: 0.837%Boothbay Fund Management LLCBought 10,174 shares on 8/15/2023Ownership: 0.024%Wells Fargo & Company MNBought 3,150 shares on 8/15/2023Ownership: 0.013%Royal Bank of CanadaBought 1,535 shares on 8/15/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions TYRA Stock - Frequently Asked Questions Should I buy or sell Tyra Biosciences stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TYRA shares. View TYRA analyst ratings or view top-rated stocks. What is Tyra Biosciences' stock price forecast for 2023? 3 brokers have issued 12 month price targets for Tyra Biosciences' stock. Their TYRA share price forecasts range from $20.00 to $27.00. On average, they predict the company's share price to reach $24.00 in the next year. This suggests a possible upside of 78.3% from the stock's current price. View analysts price targets for TYRA or view top-rated stocks among Wall Street analysts. How have TYRA shares performed in 2023? Tyra Biosciences' stock was trading at $7.60 at the beginning of 2023. Since then, TYRA stock has increased by 77.1% and is now trading at $13.46. View the best growth stocks for 2023 here. When is Tyra Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our TYRA earnings forecast. How were Tyra Biosciences' earnings last quarter? Tyra Biosciences, Inc. (NASDAQ:TYRA) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.03. What ETF holds Tyra Biosciences' stock ? Range Cancer Therapeutics ETF holds 7,883 shares of TYRA stock, representing 1.17% of its portfolio. When did Tyra Biosciences IPO? (TYRA) raised $100 million in an initial public offering on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share. What is Tyra Biosciences' stock symbol? Tyra Biosciences trades on the NASDAQ under the ticker symbol "TYRA." Who are Tyra Biosciences' major shareholders? Tyra Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BVF Inc. IL (6.37%), BlackRock Inc. (2.09%), JPMorgan Chase & Co. (0.99%), Perceptive Advisors LLC (0.84%), Geode Capital Management LLC (0.68%) and State Street Corp (0.60%). Insiders that own company stock include Boxer Capital, Llc, Daniel Bensen, Mva Investors, Llc and Todd Harris. View institutional ownership trends. How do I buy shares of Tyra Biosciences? Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tyra Biosciences' stock price today? One share of TYRA stock can currently be purchased for approximately $13.46. How much money does Tyra Biosciences make? Tyra Biosciences (NASDAQ:TYRA) has a market capitalization of $578.93 million. The company earns $-55,330,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. How can I contact Tyra Biosciences? Tyra Biosciences' mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The official website for the company is www.tyra.bio. The company can be reached via phone at 619-728-4760 or via email at aconrad@tyra.bio.. This page (NASDAQ:TYRA) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.